Necrostatin-1, RIP1/RIP3 inhibitor, relieves transforming growth factor β-induced wound-healing process in formation of hypertrophic scars

J Cosmet Dermatol. 2021 Aug;20(8):2612-2618. doi: 10.1111/jocd.13860. Epub 2020 Dec 11.

Abstract

Background: Hypertrophic scars (HS) are common pathologic processes emerged during wound-healing process. The receptor-interacting protein kinase (RIP) might participate in keloid formation.

Aims: This study aimed to investigate Necrostatin-1 (Nec-1), a RIP1/RIP3 inhibitor, in the formation of hypertrophic scar.

Methods: Human hypertrophic scar fibroblasts (HSF) were extracted from patients with hypertrophic scar. Transforming growth factor-β1 (TGF-β1) was performed to induce wound-healing process including cell proliferation (CCK-8, Flow cytometry, and Western blot), migration (Transwell assay, Western blot), collagen production (Western blot), and extracellular matrix dysfunction (Western blotting and immunofluorescence).

Results: Our results reported that Nec-1 inhibited TGF-β1-induced cell proliferation and promoted G0/G1 phase arrest in HSF. In addition, Nec-1 attenuated TGF-β1-induced cell migration and inhibited the expression of MMP2 and MMP9 in TGF-β1-induced HSF. Besides, Nec-1 also reduced TGF-β1-induced collagen production and α-smooth muscle actin expression in HSF.

Conclusions: The present data in this study showed the potential role of Nec-1 as a novel treatment for HS.

Keywords: hypertrophic scars; necrostatin-1; receptor-interacting protein kinase; transforming growth factor β; wound healing.

MeSH terms

  • Cells, Cultured
  • Cicatrix, Hypertrophic* / drug therapy
  • Cicatrix, Hypertrophic* / pathology
  • Fibroblasts / pathology
  • Humans
  • Imidazoles / pharmacology
  • Indoles
  • Transforming Growth Factor beta
  • Transforming Growth Factor beta1

Substances

  • Imidazoles
  • Indoles
  • Transforming Growth Factor beta
  • Transforming Growth Factor beta1
  • necrostatin-1